OKYO Pharma Limited (OKYO)

NASDAQ: OKYO · IEX Real-Time Price · USD
2.43
+0.11 (4.74%)
Feb 6, 2023, 12:36 PM EST - Market open
4.74%
Market Cap 52.90M
Revenue (ttm) n/a
Net Income (ttm) -6.70M
Shares Out 21.77M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,741
Open 2.21
Previous Close 2.32
Day's Range 2.21 - 2.43
52-Week Range 1.61 - 6.11
Beta 0.02
Analysts Buy
Price Target 3.50 (+44.03%)
Earnings Date n/a

About OKYO

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 17, 2022
Employees 7
Stock Exchange NASDAQ
Ticker Symbol OKYO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for OKYO stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 44.03% from the latest price.

Price Target
$3.5
(44.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DE...

1 month ago - GlobeNewsWire

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-

1 month ago - GlobeNewsWire

OKYO to Participate at Biotech Showcase

LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye di...

1 month ago - GlobeNewsWire

OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye di...

2 months ago - GlobeNewsWire

OKYO Pharma Limited - Change of Auditor

LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye di...

2 months ago - GlobeNewsWire

OKYO Pharma Limited – PDMR dealing

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye dise...

2 months ago - GlobeNewsWire

OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease

- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-

2 months ago - GlobeNewsWire

OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

Monday, November 14 th @ 8 am ET, registration details below

3 months ago - GlobeNewsWire

OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference

New York, New York--(Newsfile Corp. - October 20, 2022) - OKYO Pharma Ltd. (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to ad...

3 months ago - Newsfile Corp

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat inf...

5 months ago - GlobeNewsWire

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

NEW YORK, NY / ACCESSWIRE / September 8 2022 / OKYO Pharma Limited (NASDAQ:OKYO); (LSE:OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory ...

5 months ago - Accesswire

OKYO Pharma Limited: Result of Annual General Meeting

LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approa...

5 months ago - GlobeNewsWire

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

LONDON & NEW YORK & NORTH AUGUSTA, S.C.--(BUSINESS WIRE)-- #DryEye--OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules t...

5 months ago - Business Wire

OKYO Pharma Limited - Final audited results for the year ended 31 March 2022

LONDON and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2022.

6 months ago - GlobeNewsWire